Core Viewpoint - The Gansu Provincial Science and Technology Department and other six departments have issued a plan to support the Lanzhou High-tech Zone in promoting the biopharmaceutical industry, aiming to enhance its high-quality development and establish it as a significant biopharmaceutical hub in China [1] Group 1: Industry Development - The Lanzhou High-tech Zone has developed a complete biopharmaceutical industry system, including modern traditional Chinese medicine, biological products, medical devices, and biotechnology services, with over 200 enterprises and a stable industry chain output value of approximately 24 billion [2] - The zone has ranked among the top 50 in the national comprehensive competitiveness evaluation of biopharmaceutical industrial parks for two consecutive years, and its biopharmaceutical manufacturing innovation cluster has been recognized as one of 46 national innovation industry clusters [2] Group 2: Policy Support - The newly issued plan focuses on key areas such as technology research and development, resource supply, and market access, creating a comprehensive support system from laboratory to industrialization [3] - By the end of 2027, the Lanzhou High-tech Zone aims to achieve a total output value of over 30 billion in the biopharmaceutical industry, develop 2-3 innovative drugs, 3-5 new medical device products, and cultivate 2-3 major products with annual sales exceeding 500 million [3] Group 3: Company Initiatives - Companies in the Lanzhou High-tech Zone are seizing opportunities to accelerate their development, with firms like Zhongnong Weite focusing on new vaccine research and aiming for multiple new veterinary drug registrations [4] - Lanzhou Mingde Pharmaceutical is advancing its research on animal-derived collagen protein, leveraging policy support to enhance its confidence in the high-end medical device sector [4] - Various enterprises are making significant progress in their respective fields, with Haotian Technology becoming a supplier for 12 of the world's top 50 pharmaceutical companies and Zhongnong Weite passing GMP acceptance for its new production line [4]

Core Viewpoint - Gansu Province has introduced a policy plan to support the biopharmaceutical industry in the Lanzhou High-tech Zone, aiming to enhance innovation and promote sustainable development in the sector [1][2]. Group 1: Policy Implementation - The plan focuses on supporting the industrialization of gene and cell therapies, AI in pharmaceuticals, new vaccines, and precision diagnostics [2]. - A three-tiered collaborative approach will be adopted to address the needs of trial tasks and optimize work measures [2]. - The plan includes establishing a project list for innovative medical devices and providing a "green channel" for product registration and approval processes [2]. Group 2: Industry Goals - By the end of 2027, the total output value of the biopharmaceutical industry in Lanzhou High-tech Zone is expected to exceed 30 billion yuan [3]. - The plan aims to develop 3-5 generic drugs or biological products, 2-3 innovative drugs, and 3-5 new medical devices [3]. - The goal includes introducing over 20 high-level talents in the biopharmaceutical field and establishing more than 10 biopharmaceutical companies in the national base [3]. Group 3: Company Opportunities - Companies like Lanzhou Mingde Pharmaceutical Co. are positioned to benefit from the plan, focusing on the full industrial chain development of sheep placenta [3]. - The plan aligns with ongoing research projects in collaboration with local universities, enhancing the company's competitive edge in the biopharmaceutical market [3]. - Zhongnong Weite Biotechnology Co. is also leveraging the plan to develop new vaccines, targeting significant animal disease prevention needs [4].